UC II is a natural ingredient which contains a glycosylated, undenatured type II collagen. Previous studies have shown that small www.selleckchem.com/products/Dasatinib.html doses of UC II modulate joint health in both OA and RA. Tong et al, using an in vivo model Inhibitors,Modulators,Libraries of collagen induced arthritis, demonstrated that ingesting microgram quantities of undenatured type II collagen significantly reduces circulat ing levels of inflammatory cytokines, potentially serving to decrease both the incidence and the severity of arthritis. The ability to alter immunity via the ingestion of a food, or an antigen, is called oral tolerance. This is an on going normal physiological process that protects the ali mentary tract against untoward immunological damage. Research into its mechanism of action has revealed that several distinct types of T regulator cells mediate this phenomenon by releasing IL 10 and TGF B.

It has also been shown that this effect is transitory in nature requiring that the food, or antigen, be consumed con tinuously in order to maintain the tolerogenic state. Given these findings, plus our current understand ing of the role of various cytokines in normal joint physiology, Inhibitors,Modulators,Libraries it was hypothesized that supplementation with UC II might relieve joint discomfort and restore joint function in healthy subjects. Inhibitors,Modulators,Libraries The aim of this randomized, double blind, placebo controlled study was to assess the impact of UC II on knee function in otherwise healthy subjects with no prior history of arthritic disease who experienced knee pain upon strenuous physical exertion.

The primary effi cacy variable for assessing knee Inhibitors,Modulators,Libraries function included mea surements of flexibility using range of motion goniometry. Methods Investigational product The investigational study product UC II is derived Inhibitors,Modulators,Libraries from chicken sternum. It is manufactured using a patented, low temperature process to preserve its native structure. For the clinical study, 40 mg of UC II material, which provides 10. 4 1. 3 mg of native type II collagen, was encapsulated in an opaque capsule with excipients. Placebo was dispensed in an identical capsule containing only excip ients. Both study materials were prepared in a good manufacturing practice certified facility and provided by InterHealth Nutraceuticals, Inc. Subjects were instructed to take one capsule daily with water before bedtime. Recruitment of subjects One hundred and six subjects were screened for eligibil ity using the inclusion exclusion criteria defined in Table 1. Only healthy adults who presented with no knee joint pain at rest and no diagnosable markers indicative of active arthritic disease, as outlined by the American College of Rheumatology guidelines, were admitted into the study. selleckchem Brefeldin A To accomplish this, all potential subjects were screened by a board certified clinician.